tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Qin J et al. Radiological and clinical findings of 25 patients with invasive pulmonary aspergillosis: retrospective analysis of 2150 liver transplantation cases. 2012 Br J Radiol pmid:22496071
Anoopkumar-Dukie S et al. Mitochondrial modulation of oxygen-dependent radiosensitivity in some human tumour cell lines. 2009 Br J Radiol pmid:19366737
Murphy GJ et al. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. 2003 Br J Surg pmid:12808614
Middleton SJ et al. Adult small intestinal transplantation in England and Wales. 2003 Br J Surg pmid:12808622
Morris-Stiff GJ et al. Sequential changes in plasma selenium concentration after cadaveric renal transplantation. 2004 Br J Surg pmid:14991636
Wilson CH et al. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. 2005 Br J Surg pmid:15856479
Waller JR et al. Effects of the combination of rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia. 2002 Br J Surg pmid:12390379
Brook NR et al. Fibrosis-associated gene expression in renal transplant glomeruli after acute renal allograft rejection. 2003 Br J Surg pmid:12905557
Jain S et al. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. 2000 Br J Surg pmid:11091246
Bicknell GR et al. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. 2000 Br J Surg pmid:11091247
White DJ Immunosuppression for heart transplantation. 1993 Br. J. Biomed. Sci. pmid:7694717
Reichert TE et al. The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. 1999 Br. J. Cancer pmid:10555752
Andersson Y et al. Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. 2009 Br. J. Cancer pmid:19773757
Chambers CA Topical tacrolimus for cutaneous lupus erythematosus. 2003 Br. J. Dermatol. pmid:12752154
Ludwig E et al. New treatment modalities for granuloma faciale. 2003 Br. J. Dermatol. pmid:14511001
Vecchietti G et al. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. 2003 Br. J. Dermatol. pmid:12752158
Bens G et al. Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. 2003 Br. J. Dermatol. pmid:12890237
Reich K et al. Topical tacrolimus for pyoderma gangrenosum. 1998 Br. J. Dermatol. pmid:9892935
Danby SG and Cork MJ The effects of pimecrolimus on the innate immune response in atopic dermatitis. 2013 Br. J. Dermatol. pmid:23362967
Murrell DF et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. 2007 Br. J. Dermatol. pmid:17935515
Schmitt J et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. 2011 Br. J. Dermatol. pmid:20819086
Liao YH et al. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. 2007 Br. J. Dermatol. pmid:17935517
Schauber J et al. Topical treatment of perianal eczema with tacrolimus 0.1%. 2009 Br. J. Dermatol. pmid:19575757
Rustin MH The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. 2007 Br. J. Dermatol. pmid:17854353
Bunker CB Male genital lichen sclerosus and tacrolimus. 2007 Br. J. Dermatol. pmid:17854373
Wu CS et al. FK506 inhibits the enhancing effects of transforming growth factor (TGF)-β1 on collagen expression and TGF-β/Smad signalling in keloid fibroblasts: implication for new therapeutic approach. 2012 Br. J. Dermatol. pmid:22540338
Tennis P et al. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. 2011 Br. J. Dermatol. pmid:21466537
Braza TJ et al. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. 2003 Br. J. Dermatol. pmid:12828755
Vidal D and Alomar A Successful treatment of periostomal pyoderma gangrenosum using topical tacrolimus. 2004 Br. J. Dermatol. pmid:14996128
Lan CC et al. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. 2011 Br. J. Dermatol. pmid:21039414
Carroll CL et al. Better medication adherence results in greater improvement in severity of psoriasis. 2004 Br. J. Dermatol. pmid:15491434
Wenzel J et al. Successful treatment of recalcitrant Wegener's granulomatosis of the skin with tacrolimus (Prograf). 2004 Br. J. Dermatol. pmid:15491443
Chung BY et al. The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients: a comparative study between once-weekly and thrice-weekly applications. 2013 Br. J. Dermatol. pmid:23110605
Kabashima K et al. Treatment of eosinophilic pustular folliculitis (Ofuji's disease) with tacrolimus ointment. 2004 Br. J. Dermatol. pmid:15491457
Esquivel-Pedraza L et al. Treatment of oral lichen planus with topical pimecrolimus 1% cream. 2004 Br. J. Dermatol. pmid:15099380
Aguilar-Bernier M et al. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. 2005 Br. J. Dermatol. pmid:15840123
Sorgentini C et al. Lichen striatus in an adult: successful treatment with tacrolimus. 2004 Br. J. Dermatol. pmid:15099383
Dissemond J et al. Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. 2004 Br. J. Dermatol. pmid:15099387
Harth W and Linse R Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. 2004 Br. J. Dermatol. pmid:15099394
Higgins E and Collins P Recurrent bullous erythema multiforme treated with topical tacrolimus 0·1% ointment. 2011 Br. J. Dermatol. pmid:21114481
Kanekura T et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. 2003 Br. J. Dermatol. pmid:12588393
Vente C et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. 1999 Br. J. Dermatol. pmid:10233234
Lyon CC et al. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. 1999 Br. J. Dermatol. pmid:10233300
Jolles S et al. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. 1999 Br. J. Dermatol. pmid:10233301
Walker SL et al. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. 2002 Br. J. Dermatol. pmid:12174136
Mrowietz U et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. 1998 Br. J. Dermatol. pmid:9990361
Anstey A Therapeutic advances and shift in disease paradigm for atopic dermatitis. 2008 Br. J. Dermatol. pmid:19036027
McElwee KJ et al. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. 1997 Br. J. Dermatol. pmid:9390322
Hoeger PH et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. 2009 Br. J. Dermatol. pmid:19067708
Fujimoto N et al. Facial lichen striatus: successful treatment with tacrolimus ointment. 2003 Br. J. Dermatol. pmid:12653755
Ueda M et al. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. 2003 Br. J. Dermatol. pmid:12653761
Lan CC et al. FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. 2004 Br. J. Dermatol. pmid:15377358
Piram M et al. Short- and long-term outcome of linear morphoea in children. 2013 Br. J. Dermatol. pmid:24032480
Reitamo S et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. 2004 Br. J. Dermatol. pmid:15030341
Chuh AA The application of topical tacrolimus in vesicular pemphigoid. 2004 Br. J. Dermatol. pmid:15030368
Gollnick H et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. 2008 Br. J. Dermatol. pmid:18341665
Hjelmgren J et al. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. 2007 Br. J. Dermatol. pmid:17263826
Volz T et al. Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. 2008 Br. J. Dermatol. pmid:18647310
Nissi R et al. Altered p53 and Bcl-2 expression in keratinocytes of vulvar lichen sclerosus during pimecrolimus treatment. 2009 Br. J. Dermatol. pmid:19659469
Lan CC et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. 2005 Br. J. Dermatol. pmid:16120133
Ständer S et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. 2007 Br. J. Dermatol. pmid:17388925
Rigopoulos D et al. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. 2009 Br. J. Dermatol. pmid:19120329
Oranje AP et al. Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis. 2009 Br. J. Dermatol. pmid:18795918
Wataya-Kaneda M et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. 2011 Br. J. Dermatol. pmid:21692771
Spergel JM et al. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. 2007 Br. J. Dermatol. pmid:17573885
Taher ZA et al. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. 2009 Br. J. Dermatol. pmid:19438859
Undre NA et al. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. 2009 Br. J. Dermatol. pmid:19076975
Caproni M et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. 2007 Br. J. Dermatol. pmid:17223872
Bilenchi R et al. Human papillomavirus reactivation following topical tacrolimus therapy of anogenital lichen sclerosus. 2007 Br. J. Dermatol. pmid:17223903
Niwa Y et al. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. 2003 Br. J. Dermatol. pmid:14632799
Mashiko M et al. A case of angiolymphoid hyperplasia with eosinophilia successfully treated with tacrolimus ointment. 2006 Br. J. Dermatol. pmid:16536847
Ko MJ and Chu CY Topical tacrolimus therapy for localized bullous pemphigoid. 2003 Br. J. Dermatol. pmid:14632824
Böhm M et al. Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. 2004 Br. J. Dermatol. pmid:15327576
Kreuter A et al. Pimecrolimus 1% cream for perianal atopic dermatitis. 2005 Br. J. Dermatol. pmid:15656832
Fiorentino DF et al. The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes. 2011 Br. J. Dermatol. pmid:21166661
Lewis FM and Neill SM Safety of calcineurin inhibitors in the management of lichen sclerosis. 2007 Br. J. Dermatol. pmid:17535239
Neckermann G et al. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. 2000 Br. J. Dermatol. pmid:10792216
Ramsay HM and Harden PN Cyclosporin-induced flushing in a renal transplant recipient resolving after substitution with tacrolimus. 2000 Br. J. Dermatol. pmid:10792253
Ellis C et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. 2003 Br. J. Dermatol. pmid:12694268
Hengge UR et al. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. 2006 Br. J. Dermatol. pmid:17034535
Kang HY and Choi YM FK506 increases pigmentation and migration of human melanocytes. 2006 Br. J. Dermatol. pmid:17034537
Lübbe J and Sorg O Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice. 2004 Br. J. Dermatol. pmid:15606530
Burkhart CG and Burkhart CN Tacrolimus and topical steroids: which is more effective? 2004 Br. J. Dermatol. pmid:15606537
Tzung TY et al. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. 2007 Br. J. Dermatol. pmid:17199600
Lee DH et al. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. 2008 Br. J. Dermatol. pmid:18363758
Moreno-Arias GA et al. Plasma cell balanitis treated with tacrolimus 0.1%. 2005 Br. J. Dermatol. pmid:16307659
Lonowski S et al. Vitiligo: a potential autoimmune sequela of DRESS syndrome. 2016 Br. J. Dermatol. pmid:27038429
Bhol KC and Schechter PJ Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. 2005 Br. J. Dermatol. pmid:15948987
Reitamo S et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. 2005 Br. J. Dermatol. pmid:15948994
Bos JD Topical tacrolimus and pimecrolimus are not associated with skin atrophy. 2002 Br. J. Dermatol. pmid:11903264
Wolff K et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. 2005 Br. J. Dermatol. pmid:15948996
Rigopoulos D et al. Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. 2005 Br. J. Dermatol. pmid:15949015
Kirtschig G et al. Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. 2002 Br. J. Dermatol. pmid:12207624
Pereira U et al. Mechanisms of the sensory effects of tacrolimus on the skin. 2010 Br. J. Dermatol. pmid:20302583
Grassberger M et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. 1999 Br. J. Dermatol. pmid:10468798
Ho N et al. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. 2011 Br. J. Dermatol. pmid:21457214
Rigopoulos D et al. Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. 2006 Br. J. Dermatol. pmid:16792767
Weissenbacher S et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. 2007 Br. J. Dermatol. pmid:17493072
Williams HC Preventing eczema flares with topical corticosteroids or tacrolimus: which is best? 2011 Br. J. Dermatol. pmid:21271989
Takeuchi S et al. Pruritus of patients with atopic dermatitis in daily life and their experience of therapeutic effects: results of a web-based questionnaire survey. 2015 Br. J. Dermatol. pmid:25421804